原标题:医健IPO解码|褪去 “新冠概念”的“赶考人”:如何重塑竞争力? 21世纪经济报道记者 韩利明 上海报道 2025年开年尚不足两个月,已至少有9家生物医药领域的公司向港交所递交了IPO招股书。其中不乏迈威生物(688062.SH)、恒瑞医药(600276.SH)和百利天恒(688506.SH)三家已在A股上市的药企冲刺港股。 而作为此前“新冠概念”中的明星药企,旺山旺水和真实...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.